Toll Free: 1-888-928-9744

Johnson & Johnson - Product Pipeline Review - 2016

Published: Mar 22, 2016 | Pages: 423 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Johnson & Johnson - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Johnson & Johnson - Product Pipeline Review - 2016', provides an overview of the Johnson & Johnson's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Johnson & Johnson, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Johnson & Johnson
- The report provides overview of Johnson & Johnson including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Johnson & Johnson's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Johnson & Johnson's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Johnson & Johnson's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Johnson & Johnson
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Johnson & Johnson's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 7 Johnson & Johnson Snapshot 8 Johnson & Johnson Overview 8 Key Information 8 Key Facts 8 Johnson & Johnson - Research and Development Overview 9 Key Therapeutic Areas 9 Johnson & Johnson - Pipeline Review 19 Pipeline Products by Stage of Development 19 Pipeline Products - Monotherapy 20 Pipeline Products - Combination Treatment Modalities 21 Pipeline Products - Partnered Products 22 Pipeline Products - Out-Licensed Products 25 Johnson & Johnson - Pipeline Products Glance 27 Johnson & Johnson - Late Stage Pipeline Products 27 Johnson & Johnson - Clinical Stage Pipeline Products 30 Johnson & Johnson - Early Stage Pipeline Products 34 Johnson & Johnson - Unknown Stage Pipeline Products 39 Johnson & Johnson - Drug Profiles 40 (canagliflozin + metformin hydrochloride XR) 40 bedaquiline fumarate 41 daratumumab 44 ustekinumab 48 bortezomib 51 golimumab 57 tipifarnib 60 (cobicistat + darunavir + emtricitabine + tenofovir alafenamide) 63 (naproxen sodium + sumatriptan succinate) 65 abiraterone acetate 67 canagliflozin 70 esketamine hydrochloride 72 fulranumab 75 guselkumab 78 imetelstat sodium 81 infliximab 84 JNJ-56021927 86 rivaroxaban 88 sirukumab 94 tapentadol hydrochloride IR 97 trabectedin 99 JNJ-54861911 105 (AL-335 + odalasvir + simeprevir) 107 AL-335 108 ALS-8176 109 Cell Therapy for HIV-1 Infection 110 CNTO-3157 111 CNTO-6785 112 erdafitinib 114 JNJ-39393406 116 JNJ-40411813 118 JNJ-42039556 119 JNJ-42847922 121 JNJ-49095397 123 JNJ-53718678 125 JNJ-56022473 126 JNJ-56914845 127 JNJ-872 129 odalasvir 131 ORM-12741 132 quisinostat hydrochloride 133 rilpivirine 135 siltuximab 138 sovaprevir 141 TMC-310911 143 toreforant tartrate 144 CNTO-2476 146 COVA-322 147 telaprevir 148 Vaccine for Prostate Cancer 152 ACH-3422 155 AL-794 156 ALS-8112 157 CNTO-7160 158 EVT-100 Series 159 EVT-103 160 JNJ-18038683 162 JNJ-38877618 164 JNJ-42721458 165 JNJ-47910382 166 JNJ-49122944 167 JNJ-54175446 168 JNJ-55375515 169 JNJ-55920839 170 JNJ-56136379 171 JNJ-61610588 172 JNJ-64052781 173 JNJ-757 174 JNJ-809 176 NVR-3778 177 RV-1162 179 RV-1729 180 TOP-1288 181 Small Molecules for Rhinovirus Infections 182 Small Molecules to Inhibit Viral RNA Polymerase for RSV Infections 183 AL-516 184 CNTO-530 185 COVA-208 186 COVA-420 187 COVA-493 188 COVA-494 189 DiTU 190 flubendazole 192 Gene Therapy for Arteriosclerosis and Endothelial Dysfunction 194 JNJ-26070109 195 JNJ-26993135 196 JNJ-28307474 197 JNJ-28312141 198 JNJ-28610244 199 JNJ-31020028 200 JNJ-35815208 201 JNJ-375 202 JNJ-39729209 203 JNJ-39933673 204 JNJ-40279486 205 JNJ-40413269 206 JNJ-41477670 207 JNJ-42314415 208 JNJ-42905343 209 JNJ-46778212 210 JNJ-47965567 211 JNJ-5234801 212 JNJ-54416076 213 Monoclonal Antibodies to Inhibit TGF-beta 1 for Fibrosis 214 Monoclonal Antibody for Autoimmune Diseases 215 Nucleozin 216 Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases 217 Recombinant Protein-1 for Undisclosed Indication 218 Recombinant Protein-2 for Undisclosed Indication 219 Recombinant Proteins for Inflammatory and Autoimmune Diseases 220 RV-1088 221 S-961 222 Small Molecule to Inhibit Capsid Protein for Hepatitis B 223 Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia 224 Small Molecule to Inhibit FLT3 for AML 225 Small Molecule to Inhibit PDE10A for Schizophrenia 226 Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity 227 Small Molecules to Antagonize P2X7 for Central Nervous System 228 Small Molecules to Inhibit FMS for Rheumatoid Arthritis 229 Stem Cell Therapy for Type 1 and Type 2 Diabetes 230 VE-202 231 ALS-2135 232 Cellular Immunotherapy for Solid Tumors 233 Drugs for Cancer 234 Drugs for Prostate Cancer 235 influenza vaccine 236 LCTA-949 237 Peptides to Inhibit Ion Channel for Chronic Pain 238 Recombinant Protein for Inflammatory Bowel Diseases 239 Small Molecule to Inhibit cccDNA for Hepatitis B 240 Small Molecule to Inhibit Kinase for Autoimmune Diseases 241 Small Molecules for Central Nervous System Disorders 242 Small Molecules for Hepatitis B 243 Small Molecules for Lymphoma 244 Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer 245 Small Molecules to Antagonize CCR2 for Type II Diabetes 246 Small Molecules to Block Cav2.2 Channel for Chronic Pain 247 TMC-207 Back Up 248 VX-353 249 Biologics for Undisclosed Indication 250 JNJ-40346527 251 RV-6153 253 Johnson & Johnson - Pipeline Analysis 254 Johnson & Johnson - Pipeline Products by Target 254 Johnson & Johnson - Pipeline Products by Route of Administration 262 Johnson & Johnson - Pipeline Products by Molecule Type 263 Johnson & Johnson - Pipeline Products by Mechanism of Action 264 Johnson & Johnson - Recent Pipeline Updates 275 Johnson & Johnson - Dormant Projects 381 Johnson & Johnson - Discontinued Pipeline Products 386 Discontinued Pipeline Product Profiles 386 Johnson & Johnson - Company Statement 389 Johnson & Johnson - Locations And Subsidiaries 391 Head Office 391 Other Locations & Subsidiaries 391 Appendix 412 Methodology 412 Coverage 412 Secondary Research 412 Primary Research 412 Expert Panel Validation 412 Contact Us 412 Disclaimer 413
List of Tables
Johnson & Johnson, Key Information 18 Johnson & Johnson, Key Facts 18 Johnson & Johnson - Pipeline by Indication, 2016 20 Johnson & Johnson - Pipeline by Stage of Development, 2016 29 Johnson & Johnson - Monotherapy Products in Pipeline, 2016 30 Johnson & Johnson - Combination Treatment Modalities in Pipeline, 2016 31 Johnson & Johnson - Partnered Products in Pipeline, 2016 32 Johnson & Johnson - Partnered Products/ Combination Treatment Modalities, 2016 33 Johnson & Johnson - Out-Licensed Products in Pipeline, 2016 35 Johnson & Johnson - Out-Licensed Products/ Combination Treatment Modalities, 2016 36 Johnson & Johnson - Pre-Registration, 2016 37 Johnson & Johnson - Filing rejected/Withdrawn, 2016 38 Johnson & Johnson - Phase III, 2016 39 Johnson & Johnson - Phase II, 2016 40 Johnson & Johnson - Phase I, 2016 42 Johnson & Johnson - IND/CTA Filed, 2016 44 Johnson & Johnson - Preclinical, 2016 45 Johnson & Johnson - Discovery, 2016 48 Johnson & Johnson - Unknown, 2016 49 Johnson & Johnson - Pipeline by Target, 2016 264 Johnson & Johnson - Pipeline by Route of Administration, 2016 272 Johnson & Johnson - Pipeline by Molecule Type, 2016 273 Johnson & Johnson - Pipeline Products by Mechanism of Action, 2016 274 Johnson & Johnson - Recent Pipeline Updates, 2016 285 Johnson & Johnson - Dormant Developmental Projects,2016 391 Johnson & Johnson - Discontinued Pipeline Products, 2016 396 Johnson & Johnson, Subsidiaries 401


List of Figures
Johnson & Johnson - Pipeline by Top 10 Indication, 2016 20 Johnson & Johnson - Pipeline by Stage of Development, 2016 29 Johnson & Johnson - Monotherapy Products in Pipeline, 2016 30 Johnson & Johnson - Combination Treatment Modalities in Pipeline, 2016 31 Johnson & Johnson - Partnered Products in Pipeline, 2016 32 Johnson & Johnson - Out-Licensed Products in Pipeline, 2016 35 Johnson & Johnson - Pipeline by Top 10 Target, 2016 264 Johnson & Johnson - Pipeline by Top 10 Route of Administration, 2016 272 Johnson & Johnson - Pipeline by Top 10 Molecule Type, 2016 273 Johnson & Johnson - Pipeline Products by Top 10 Mechanism of Action, 2016 274

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...

U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposable

Read More...

Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growi

Read More...

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...
Choose License Type
Single User - US $1500
Multi User - US $3000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify